Foster Victor Wealth Advisors LLC Raises Stock Position in AbbVie Inc. $ABBV

Foster Victor Wealth Advisors LLC increased its position in shares of AbbVie Inc. (NYSE:ABBV) by 4.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 79,462 shares of the company’s stock after acquiring an additional 3,209 shares during the period. AbbVie makes up about 1.2% of Foster Victor Wealth Advisors LLC’s holdings, making the stock its 26th biggest position. Foster Victor Wealth Advisors LLC’s holdings in AbbVie were worth $18,587,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. TD Capital Management LLC increased its holdings in shares of AbbVie by 82.9% in the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after purchasing an additional 58 shares during the period. Marshall & Sullivan Inc. WA purchased a new position in AbbVie during the second quarter worth about $25,000. Evolution Wealth Management Inc. bought a new position in AbbVie in the 2nd quarter worth about $26,000. Spurstone Advisory Services LLC purchased a new stake in shares of AbbVie in the 2nd quarter valued at about $28,000. Finally, Financial Gravity Companies Inc. bought a new stake in shares of AbbVie during the 2nd quarter valued at about $36,000. 70.23% of the stock is owned by institutional investors.

AbbVie Stock Performance

NYSE ABBV opened at $227.44 on Monday. The company has a 50-day simple moving average of $226.63 and a two-hundred day simple moving average of $211.31. The company has a quick ratio of 0.60, a current ratio of 0.72 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The firm has a market cap of $401.98 billion, a price-to-earnings ratio of 172.30, a PEG ratio of 1.29 and a beta of 0.36.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter in the previous year, the business earned $3.00 earnings per share. The company’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a $1.73 dividend. The ex-dividend date is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.0%. AbbVie’s dividend payout ratio is presently 496.97%.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on ABBV shares. DZ Bank cut shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective on the stock. in a research report on Tuesday, November 4th. JPMorgan Chase & Co. boosted their price target on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. Erste Group Bank cut shares of AbbVie from a “buy” rating to a “hold” rating in a research report on Tuesday, October 14th. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and upped their target price for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Finally, Citigroup lowered their price target on AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a research report on Monday, November 3rd. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $245.84.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.